MALVERN, Pa., Oct. 26 /PRNewswire/ -- Ascenta Therapeutics announced today that encouraging results from a Phase I dose-escalation study of two combination therapy regimens containing AT-101, an oral, pan-Bcl-2 inhibitor, in patients with the most malignant type of brain tumor, were described in an oral presentation at the 2009 Joint Meeting of the Society for NeuroOncology (SNO) and AANS/CNS Section on Tumors in New Orleans, Louisiana (Concurrent Session VI: Radiation Oncology, October 23, 2009; Abstract # 449).
The study, conducted through the Adult Brain Tumor Consortium (ABTC), formerly the New Approaches to Brain Tumor Therapy (NABTT) consortium, enrolled 16 patients with newly diagnosed glioblastoma multiforme who received either AT-101 administered concurrently with temozolomide and radiation therapy (Arm 1) or AT-101 as a component of temozolomide adjuvant therapy after chemoradiation (Arm 2). At the time of analysis, six of the 16 patients remained alive, with median survival times of 15.1 months and 18.1 months for Arm 1 and Arm 2 respectively.
The investigators concluded that AT-101 can be administered safely with radiation therapy and temozolomide in patients with newly diagnosed glioblastoma multiforme, exhibiting a toxicity profile similar to that observed with AT-101 in the treatment of other tumor types. They also determined the recommended dose of AT-101 in both combination regimens for future studies.
About Glioblastoma Multiforme
About Ascenta Therapeutics
For additional information on Ascenta Therapeutics, please visit the company's website at www.ascenta.com
Photo: http://www.newscom.com/cgi-bin/prnh/20090227/PH75873LOGOAscenta Therapeutics, Inc.